Search - tctmd.com

Displaying 801 - 820 of 1012

Sort: Relevancy | Date

Presentation TCT 2014

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Presenter: David J. Moliterno, E. Magnus Ohman, Duane S. Pinto, Michael Lipinski

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ian T. Meredith

September 14, 2014

Presentation TCT 2014

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, Michael Boehm

September 14, 2014

Presentation TCT 2014

Optimized Comprehensive Wound Care: Elements of a Clinically Excellent and Financially Viable Program

Presenter: Roger M. Greenhalgh, Michael R. Jaff, David P. Slovut, Raghu Kolluri

September 14, 2014

Presentation TCT 2014

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Susheel Kodali

September 14, 2014

Presentation TCT 2014

Understanding the Hemodynamics of Heart Failure

Presenter: Russell A. Brandwein, Michael Guiry, Kenneth A. Gorski

September 14, 2014

Presentation TCT 2014

Randomized Trial Outcomes: POBA vs Stenting in Infrapopliteal Lesions

Presenter: Roger M. Greenhalgh, Michael R. Jaff, David P. Slovut, Karl-Ludwig Schulte

September 14, 2014

Presentation TCT 2014

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Ronald M. Lazar

September 14, 2014

Presentation TCT 2014

The Trial Got it Right: Replacement Is Favored in Functional MR!

Presenter: Michael J. Mack

September 14, 2014

Presentation TCT 2014

Strokes After TAVR II: Management Considerations (Current and Future)

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb, Nicolas M. van Mieghem

September 14, 2014

Presentation TCT 2014

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray, John Flack

September 14, 2014

Presentation TCT 2014

A Primer of the Pedal Circulation: Relevance to Revascularization Strategies

Presenter: Roger M. Greenhalgh, Michael R. Jaff, David P. Slovut, Jihad A. Mustapha

September 14, 2014

Presentation TCT 2014

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

Presenter: Samir R. Kapadia, Patrick T. O'Gara, G. Michael Deeb

September 14, 2014

Presentation TCT 2014

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Presenter: Deepak L. Bhatt, Michael A. Weber, William A. Gray

September 14, 2014

Presentation TCT 2014

Current Trends and Operational Strategies

Presenter: Michael Guiry, Regina Deible

September 14, 2014

Presentation TCT 2014

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Presenter: Kishore J. Harjai, Michael S. Lee

September 14, 2014

Presentation TCT 2014

Case #4: Swift and Safe DES for Side Branch Bail Out

Presenter: Evald H. Christiansen, George D. Dangas, Andrejs Erglis, Michael Maeng

September 14, 2014

Presentation TCT 2014

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

Presenter: Michael J. Lim, Hemal Gada

September 14, 2014

Presentation TCT 2014

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Ted E. Feldman

September 13, 2014

Presentation TCT 2014

Complications of the MitraClip: From the Common to the Unusual

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Brian K. Whisenant

September 13, 2014

Advertisement

TCT 467: Bivalirudin vs Heparin for Percutaneous Coronary Intervention: An Updated Meta-analysis of Randomized Controlled Trials

Paravalvular Regurgitation After TAVR II: Will New TAVR Systems Eliminate the Problem?

From SYMPLICITY HTN-1 to the Global SYMPLICITY Registry and Beyond: Updates from and Status of the SYMPLICITY Clinical Trial Program

Optimized Comprehensive Wound Care: Elements of a Clinically Excellent and Financially Viable Program

Paravalvular Regurgitation After TAVR I: Incidence, Etiologies, Diagnostic Considerations, Clinical Impact, and Treatment Alternatives

Understanding the Hemodynamics of Heart Failure

Randomized Trial Outcomes: POBA vs Stenting in Infrapopliteal Lesions

Neurocognitive Functional Assessment After TAVR: Methodologies and Clinical Importance

The Trial Got it Right: Replacement Is Favored in Functional MR!

Strokes After TAVR II: Management Considerations (Current and Future)

TCT 405: SYMPLICITY HTN-3: Outcomes in the African-American and NonAfrican American Populations

A Primer of the Pedal Circulation: Relevance to Revascularization Strategies

Strokes After TAVR I: Incidence (Past and Present) and Multifactorial Origin

First Deep Dive into SYMPLICITY HTN-3: Primary Results and Updated Analyses

Current Trends and Operational Strategies

Position Statement: Heparin Will Once Again Become the Anticoagulant of Choice for PCI in Stable and Unstable Coronary Syndromes

Case #4: Swift and Safe DES for Side Branch Bail Out

Valvular Heart Disease: Treatment of Mitral Stenosis and Mitral Regurgitation

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Complications of the MitraClip: From the Common to the Unusual

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content